GlobeNewswire PharmaOriginal article
Novo provides update on the denecimig Biologics License Application (BLA) in the US
BLA FilingdenecimigNeutral
AI Analysis
Summary
Novo Nordisk announced that the FDA's review of denecimig BLA for haemophilia A treatment remains ongoing with no new timeline communicated by the agency.
Outcome Details
FDA review ongoing, no new timeline communicated
Importance:5/10
Sentiment:
0.00
BLAFDAhaemophiliaregulatoryongoing review
Related Companies
Read the original article
Published by GlobeNewswire Pharma on October 2, 2026 8:53 PM